PATENT CLAIM ANALYSIS

Application Number: 15938038
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["530", "317000"]

Abstract:
The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

Claim (Index 2):
The method of  claim 1 , wherein the gastroparesis is diabetic gastroparesis or postsurgical gastroparesis syndrome.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 90.0
- Lexical Diversity: 1.58824
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15178303', '12028611', '14530311', '11149512', '12333026']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7858161602767872
- 35 USC 102 Novelty (BERT): 0.5874503617318183
- Combined Prediction Score: 0.7659795804222904
- Mean Citation Score: 500.20284
- Max Citation Score: 555.86707
- Similarity Product: 419.53246170383215

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test